Introducing GSK GSK homepage Downloads Annual report
Product portfolio



Back Next
  Hycamtin ONCOLOGY & EMESIS  
   


Hycamtin

 
     

£95m/$144m

For the second line treatment of ovarian cancer and small cell lung cancer.

 

  
         
         
      back to list  

 
    Updated March 22, 2001 - © 2001 GlaxoSmithKline - All Rights Reserved
Legal Notices - Privacy Statement
Introducing GSK
Chairman and CEO
Business operating review
Corporate citizenship
Product portfolio
Corporate executive team
Summary financials
Summary remuneration report
Responsibility statements
Corporate governance
The board
Shareholder return
Shareholder information
Contact details